Assessing amblyopia treatment using multifocal visual evoked potentials

BACKGROUND: To evaluate the effect of occlusion treatment for anisometropic amblyopia using multifocal visual evoked potentials (mfVEPs). METHODS: The patients for this study comprised 19 patients (mean age 6.05 ± 1.65 years) with anisometropic amblyopia underwent mfVEP analysis using the RETIscan® system before and after occlusion treatment. After dividing the area into six ring areas and four quadrants, we analyzed the amplitudes and latencies of the mfVEPs. RESULTS: The amplitudes of ring 1 (central field) in amblyopic eyes after treatment were significantly higher than those in the other rings (p = 0.001). The mfVEP amplitudes in each of the six rings between amblyopic eyes and fellow eyes at diagnosis and after occlusion treatment showed no significant differences. In quadrant 1 the amplitudes of the amblyopic eyes and fellow eyes were significantly different at the time of diagnosis (p = 0.005), whereas after occlusion treatment there was no significant difference (p = 0.888). The amplitudes for each of the six rings at diagnosis and after occlusion treatment in amblyopic eyes versus fellow eyes showed no significant difference. There were also no differences in the amplitudes in each of the four quadrants at the time of diagnosis and after occlusion treatment in amblyopic eyes versus fellow eyes. No significant difference was found in the comparison of latency values in each of the six rings or in each of the four quadrants at diagnosis and after occlusion treatment in amblyopic eyes versus their fellow eyes. CONCLUSIONS: The amplitudes of quadrant 1 in amblyopic eyes compared with those of the fellow eyes at diagnosis were increased after occlusion treatment. Changes of the difference between amblyopic eyes and fellow eyes in quadrant 1 after occlusion treatment could be a useful, objective method for monitoring improvement in visual acuity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12886-018-0877-0) contains supplementary material, which is available to authorized users.